font size
Sign inprintPrint
SAN FRANCISCO, CA-September 2, 2014-M&A activity propelled 2014 into the record books with the announcement of Roche's planned $8.3 billion acquisition of Intermune, the developer of a drug to treat a fatal and unexplained scarring of the lung. The agreement pushed life sciences M&A activity through the first eight months of 2014 to a record $195.7 billion, compared to the previous record of $189.7 billion for all of 2009 for therapeutics, tools, diagnostics, and digital health companies, according to Burrill Media. Read More
Other recent stories

Follow burrillreport on Twitter